← Leaderboards
Venkatram Reddy Atigadda
University Of Alabama At Birmingham
$2,912,743
Attributed
$3,088,592
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $610.1K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,088,592 · 3
By mechanism
R01$1,799,831 · 1
P01$937,063 · 1
R21$351,698 · 1
Top collaborators
- Tatjana Coric2 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Craig A Elmets$8,601,504
- Donald D Muccio$2,766,715
- Holly E Richter$12,519,508
- Natalia Y Kedishvili$11,245,175
- Alayne Denise Markland$7,052,592
Others in their field
Top investigators on “Toxic Effect”
- George R Seage · Abt Associates, Inc.$224,114,540
- Peter C Adamson · National Childhood Cancer Foundation$126,756,857
- Gregory H Reaman · National Childhood Cancer Foundation$123,836,183
- Carol Nesel · Westat$116,355,411
- Mary M Horowitz · Medical College Of Wisconsin$90,165,506
- Barney Sparrow · Battelle Memorial Institute$88,494,220
Research focus
Toxic EffectMalignant NeoplasmsStructureBexarotenePreventionAgonistPreventSerumDesignBindingNuclear ReceptorsRetinoidsLipidsLigand BindingLaboratoriesCombatCancer ChemopreventionChronicGrantExperimental StudyGenetic TranscriptionAnalogHydrogenEvaluation
Grant awards (10)
Development of Potent and non-toxic rexinoids to prevent non-melanoma skin cancer$610,112
R01 · FY2025 · CA · contact PI
Development of Potent and non-toxic rexinoids to prevent non-melanoma skin cancer$579,607
R01 · FY2024 · CA · contact PI
Development of Potent and non-toxic rexinoids to prevent non-melanoma skin cancer$610,112
R01 · FY2023 · CA · contact PI
Core 2: RXR Rexinoid Design and Synthesis$128,263
P01 · FY2021 · CA · contact PI
Core 2: RXR Rexinoid Design and Synthesis$201,786
P01 · FY2020 · CA · contact PI
Core 2: RXR Rexinoid Design and Synthesis$197,418
P01 · FY2019 · CA · contact PI
Core 2: RXR Rexinoid Design and Synthesis$204,798
P01 · FY2018 · CA · contact PI
Core 2: RXR Rexinoid Design and Synthesis$204,798
P01 · FY2017 · CA · contact PI
Chemoprevention of breast cancer with rexinoids that inhibit obesity-induced metabolic syndrome$159,863
R21 · FY2017 · CA
Chemoprevention of breast cancer with rexinoids that inhibit obesity-induced metabolic syndrome$191,835
R21 · FY2016 · CA